Loading...
Receive $200 for creating an Interactive Brokers account using our link: Create IBKR account. Read our Interactive Brokers analysis
- Ticker
- COEP
- Price
- 12.00
- Stock movement down
- -0.11 (-0.91%)
- Company name
- Coeptis Therapeutics Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 57.84M
- Ent value
- 56.20M
- Price/Sales
- 24.46
- Price/Book
- 4.44
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- 676.63%
- 1 year return (CAGR)
- -
- 3 year return (CAGR)
- -
- 5 year return (CAGR)
- -
- 10 year return (CAGR)
- -
Last updated: 2026-02-20
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
COEP does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 24.46 |
| Price to Book | 4.44 |
| EV to Sales | 23.77 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 4.82M |
| EPS (TTM) | -2.06 |
| FCF per share (TTM) | -1.76 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 2.36M |
| Gross profit (TTM) | 105.55K |
| Operating income (TTM) | -13.22M |
| Net income (TTM) | -9.76M |
| EPS (TTM) | -2.06 |
| EPS (1y forward) | - |
Margins
Loading...
Margins data
| Gross margin (TTM) | 4.46% |
| Operating margin (TTM) | -559.01% |
| Profit margin (TTM) | -412.93% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 4.91M |
| Net receivables | 86.04K |
| Total current assets | 5.99M |
| Goodwill | 0.00 |
| Intangible assets | 1.21M |
| Property, plant and equipment | 268.79K |
| Total assets | 16.28M |
| Accounts payable | 783.10K |
| Short/Current long term debt | 279.87K |
| Total current liabilities | 2.71M |
| Total liabilities | 3.26M |
| Shareholder's equity | 13.02M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -8.35M |
| Capital expenditures (TTM) | 4.00 |
| Free cash flow (TTM) | -8.35M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -75.00% |
| Return on Assets | -59.96% |
| Return on Invested Capital | -73.43% |
| Cash Return on Invested Capital | -62.81% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 12.29 |
| Daily high | 12.29 |
| Daily low | 11.45 |
| Daily Volume | 20K |
| All-time high | 18.80 |
| 1y analyst estimate | 3.00 |
| Beta | -0.50 |
| EPS (TTM) | -2.06 |
| Dividend per share | 0.00 |
| Ex-div date | - |
| Next earnings date | - |
Downside potential
Loading...
Downside potential data
| COEP | S&P500 | |
| Current price drop from All-time high | -36.17% | -1.82% |
| Highest price drop | -43.56% | -56.47% |
| Date of highest drop | 5 Feb 2026 | 9 Mar 2009 |
| Avg drop from high | -17.73% | -10.84% |
| Avg time to new high | 17 days | 12 days |
| Max time to new high | 55 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
57.84M
Marketcap category
Small-cap
Description
Coeptis Therapeutics Holdings, Inc., together with its subsidiaries, operates as a biopharmaceutical company. The company is developing cell therapy platforms for cancer, autoimmune, and infectious diseases. Its product portfolio and rights are licensed from Deverra Therapeutics, including an allogeneic cellular immunotherapy platform; and DVX201, a clinical-stage, natural killer cell therapy technology. Its product pipeline consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy; and SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological and solid tumors. In addition, the company offers its drugs for acute myeloid leukemia and acute respiratory diseases. Coeptis Therapeutics Holdings, Inc. has co-development agreement Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson's Disease. The company was founded in 2017 and is headquartered in Wexford, Pennsylvania.
Employees
5
Website
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partner